

# Eamonn M M Quigley

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9169088/eamonn-m-m-quigley-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212 papers	12,144 citations	52 h-index	109 g-index
233 ext. papers	14,835 ext. citations	6.1 avg, IF	7.08 L-index

#	Paper	IF	Citations
212	Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , <b>2005</b> , 128, 541-51	13.3	1051
211	Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1581-90	0.7	605
210	An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. <i>Gut</i> , <b>2012</b> , 61, 997-1006	19.2	564
209	Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. <i>Gastroenterology</i> , <b>2006</b> , 130, 304-11	13.3	479
208	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , <b>2010</b> , 59, 325-32	19.2	472
207	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1547-61; quiz 1546, 1562	0.7	447
206	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16014	51.1	429
205	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , <b>2009</b> , 58, 367-78	19.2	404
204	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109 Suppl 1, S2-26; quiz S27	0.7	393
203	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2008</b> , 337, a2313	5.9	368
202	Gastrointestinal symptoms in Parkinson's disease. <i>Movement Disorders</i> , <b>1991</b> , 6, 151-6	7	294
201	Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. <i>Current Neurology and Neuroscience Reports</i> , <b>2017</b> , 17, 94	6.6	290
200	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , <b>2021</b> , 160, 99-114.e3	13.3	285
199	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1350-65; quiz 1366	0.7	262
198	Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. <i>Antonie Van Leeuwenhoek</i> , <b>1999</b> , 76, 279-292	2.1	257
197	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1044-1060	6.1	248
196	Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 315-28	6.1	237

195	Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. <i>Gut Microbes</i> , <b>2013</b> , 4, 325-39	8.8	229
194	Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 745-67	6.1	205
193	The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1367-74	0.7	202
192	Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. <i>Gut</i> , <b>2012</b> , 61, 354-66	19.2	196
191	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 21-39	0.7	185
190	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1290-1300	0.7	173
189	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1-18	0.7	170
188	The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 649-667	24.2	165
187	Constipation in Parkinson's disease: objective assessment and response to psyllium. <i>Movement Disorders</i> , <b>1997</b> , 12, 946-51	7	163
186	Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. <i>Gastroenterology</i> , <b>2014</b> , 146, 1554-63	13.3	121
185	Prebiotics and Probiotics in Digestive Health. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 333-344	6.9	115
184	A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 356-66	3	106
183	Gastrointestinal symptoms in Parkinson's disease: 18-month follow-up study. <i>Movement Disorders</i> , <b>1993</b> , 8, 83-6	7	105
182	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, S8-S35	0.7	103
181	Defecatory function in Parkinson's disease: response to apomorphine. <i>Annals of Neurology</i> , <b>1993</b> , 33, 490-3	9.4	99
180	Antroduodenal manometry. Usefulness and limitations as an outpatient study. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 20-8	4	97
179	Probiotics in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 769-782	4.4	95
178	Portrait of an immunoregulatory Bifidobacterium. <i>Gut Microbes</i> , <b>2012</b> , 3, 261-6	8.8	80

177	Cisapride: what can we learn from the rise and fall of a prokinetic?. <i>Journal of Digestive Diseases</i> , <b>2011</b> , 12, 147-56	3.3	73
176	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , <b>2018</b> , 155, 1753-1763	13.3	72
175	Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 315-320	24.2	71
174	The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 1503-9	6.1	70
173	Irritable bowel syndrome: the burden and unmet needs in Europe. <i>Digestive and Liver Disease</i> , <b>2006</b> , 38, 717-23	3.3	69
172	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , <b>2020</b> , 69, 74-82	19.2	68
171	The enteric microbiota in the pathogenesis and management of constipation. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 119-26	2.5	65
170	Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center experience. <i>Journal of Clinical Gastroenterology</i> , <b>1999</b> , 28, 131-4	3	63
169	Irritable bowel syndrome: role of food in pathogenesis and management. <i>Journal of Digestive Diseases</i> , <b>2009</b> , 10, 237-46	3.3	59
168	Anorectal function in fluctuating (on-off) Parkinson disease: evaluation by combined anorectal manometry and electromyography. <i>Movement Disorders</i> , <b>1995</b> , 10, 650-7	7	59
167	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 117-131	18.8	58
166	Small intestinal bacterial overgrowth: what it is and what it is not. <i>Current Opinion in Gastroenterology</i> , <b>2014</b> , 30, 141-6	3	57
165	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , <b>2020</b> , 69, 1441-1451	19.2	53
164	Anorectal manometry in the assessment of anorectal function in Parkinson disease: a comparison with chronic idiopathic constipation. <i>Movement Disorders</i> , <b>1994</b> , 9, 655-63	7	53
163	The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). <i>Current Gastroenterology Reports</i> , <b>2019</b> , 21, 3	5	53
162	Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. <i>Nutrition in Clinical Practice</i> , <b>2012</b> , 27, 195-200	3.6	52
161	Fecal excretion of <i>Bifidobacterium infantis</i> 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. <i>Gut Microbes</i> , <b>2013</b> , 4, 201-11	8.8	52
160	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 2357-2372	4	52

159	Review article: gastric emptying in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 56-60	6.1	51
158	Prucalopride: safety, efficacy and potential applications. <i>Therapeutic Advances in Gastroenterology</i> , <b>2012</b> , 5, 23-30	4.7	49
157	Probiotics in functional gastrointestinal disorders: what are the facts?. <i>Current Opinion in Pharmacology</i> , <b>2008</b> , 8, 704-8	5.1	48
156	Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. <i>Chinese Journal of Digestive Diseases</i> , <b>2005</b> , 6, 122-32		47
155	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 199-212	4.7	44
154	The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	44
153	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , <b>2015</b> , 6, e107	4.2	37
152	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Journal of Neurogastroenterology and Motility</i> , <b>2015</b> , 21, 330-6	4.4	37
151	Review article: quality-of-life issues in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22 Suppl 1, 41-7	6.1	37
150	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , <b>2020</b> , 159, 1526-1532	13.3	33
149	Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 572-581	3.3	30
148	The QonQase. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate!. <i>Neurogastroenterology and Motility</i> , <b>2007</b> , 19, 793-7	4	28
147	The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1103-1111	6.1	27
146	The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , <b>2017</b> , 34, 2661-2673	4.1	26
145	Definition, Pathogenesis, and Management of That[Cursed]Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 467-479	6.9	25
144	Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, S24-30	0.7	25
143	Recent advances in modulating the microbiome. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	23
142	An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 1531-7	4	21

141	Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: Differing effects of cyclosporine and FK 506. <i>Hepatology</i> , <b>1994</b> , 19, 1381-1389	11.2	21
140	Bugs on the brain; brain in the gut--seeking explanations for common gastrointestinal symptoms. <i>Irish Journal of Medical Science</i> , <b>2013</b> , 182, 1-6	1.9	20
139	Probiotics in Irritable Bowel Syndrome: The Science and the Evidence. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49 Suppl 1, S60-4	3	20
138	The probiotic in the management of Coronavirus: A theoretical basis. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2020</b> , 34, 2058738420961304	3	19
137	From comic relief to real understanding; how intestinal gas causes symptoms. <i>Gut</i> , <b>2003</b> , 52, 1659-61	19.2	18
136	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. <i>Indian Journal of Gastroenterology</i> , <b>2020</b> , 39, 9-21	1.9	18
135	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , <b>2017</b> , 19, 53	5	17
134	Critical care dysmotility: abnormal foregut motor function in the ICU/ITU patient. <i>Gut</i> , <b>2005</b> , 54, 1351-2; discussion 1384-90	19.2	17
133	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region - background and recommendations of a regional consensus meeting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 57-69	4	16
132	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 312-316	7.3	16
131	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <i>Frontline Gastroenterology</i> , <b>2020</b> , 11, 62-69	2.6	16
130	Probiotics in gastrointestinal disorders. <i>Hospital Practice (1995)</i> , <b>2010</b> , 38, 122-9	2.2	15
129	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , <b>2018</b> , 67, 1425-1433	19.2	15
128	Diet and irritable bowel syndrome. <i>Current Opinion in Gastroenterology</i> , <b>2015</b> , 31, 166-71	3	14
127	Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , <b>2018</b> , 35, 967-980	4.1	14
126	Carriage of <i>Clostridium difficile</i> in outpatients with irritable bowel syndrome. <i>Journal of Medical Microbiology</i> , <b>2012</b> , 61, 1290-1294	3.2	14
125	The clinical pharmacology of motility disorders: the perils (and pearls) of prokinesia. <i>Gastroenterology</i> , <b>1994</b> , 106, 1112-4	13.3	14
124	The future of probiotics for disorders of the brain-gut axis. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 817, 417-32	3.6	13

123	THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. <i>Arquivos De Gastroenterologia</i> , <b>2015</b> , 52, 331-8	1.3	13
122	A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 149-60	2.5	13
121	New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17 Suppl 2, 43-51	6.1	13
120	Pharmacotherapy of gastroparesis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 881-7	4	13
119	Nutraceuticals as modulators of gut microbiota: Role in therapy. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 1351-1362	8.6	13
118	Basic Definitions and Concepts: Organization of the Gut Microbiome. <i>Gastroenterology Clinics of North America</i> , <b>2017</b> , 46, 1-8	4.4	12
117	Advancing treatment options for chronic idiopathic constipation. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 501-11	4	12
116	Acute Intestinal Pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , <b>2000</b> , 3, 273-286	2.5	12
115	Primary Biliary Cirrhosis and the Microbiome. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 349-353	7.3	12
114	The diagnosis of small intestinal bacterial overgrowth: Two steps forward, one step backwards?. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13494	4	12
113	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. <i>Journal of Neurogastroenterology and Motility</i> , <b>2018</b> , 24, 355-366	4.4	11
112	What is the evidence for the use of probiotics in functional disorders?. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 379-84	5	11
111	Chronic Intestinal Pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , <b>1999</b> , 2, 239-250	2.5	11
110	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. <i>Neurogastroenterology and Motility</i> , <b>2020</b> , 32, e13890	4	10
109	Epigenetics: filling in the Heritability gap and identifying gene-environment interactions in ulcerative colitis. <i>Genome Medicine</i> , <b>2012</b> , 4, 72	14.4	10
108	Commentary: synbiotics and gut microbiota in older people--a microbial guide to healthy ageing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1141-2	6.1	10
107	The Microbiome and the Liver: The Basics. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 299-305	7.3	10
106	Therapeutic implications of the gastrointestinal microbiome. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 38, 90-96	5.1	9

105	Transdermal delivery of erythromycin lactobionate--implications for the therapy of gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1997</b> , 11, 589-92	6.1	9
104	Brain Fogging and D-Lactic Acidosis: Probiotics Are Not the Cause. <i>Clinical and Translational Gastroenterology</i> , <b>2018</b> , 9, 187	4.2	9
103	Systematic review with meta-analysis: cholecystectomy for biliary dyskinesia-what can the gallbladder ejection fraction tell us?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 654-663	6.1	8
102	Emerging treatments for chronic constipation. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 365-73	3.7	8
101	Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?. <i>Clinical Medicine Gastroenterology</i> , <b>2010</b> , 3, CGast.S4136		8
100	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: in vitro study to determine the optimal threshold range. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2012</b> , 56, 289-94	1.7	7
99	Bacteria, genetics and irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2010</b> , 4, 271-6	4.2	7
98	Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 1816-23	4	7
97	Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon!. <i>Indian Journal of Medical Research</i> , <b>2014</b> , 140, 582-4	2.9	7
96	Reply to: Postbiotics - when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 827-828	24.2	7
95	Prebiotics for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2009</b> , 3, 487-92	4.2	6
94	Aerophagia and Intestinal Gas. <i>Current Treatment Options in Gastroenterology</i> , <b>2002</b> , 5, 259-265	2.5	6
93	Gastric compliance and motility in the portal hypertensive rat. <i>Journal of Investigative Surgery</i> , <b>1992</b> , 5, 109-14	1.2	6
92	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , <b>2020</b> , 159, 395-396	13.3	5
91	Home Parenteral Nutrition: Complications, Survival, Costs and Quality of Life130-141		5
90	Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2005</b> , 2, 436-7		5
89	Symptoms and the small intestinal microbiome - the unknown explored. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 457-458	24.2	4
88	Barrett's esophagus: clinical features, obesity, and imaging. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 36-52	6.5	4

87	Motility, heartburn and dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 11, 41-50	6.1	4
86	A Critical Review of the Current Clinical Landscape of Gastroparesis. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 140-145	0.7	4
85	Small Intestinal Bacterial Overgrowth, Pathophysiology and its implications for Definition and Management.. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	4
84	Pharmacoeconomic study of chronic constipation in a secondary care centre. <i>Irish Journal of Medical Science</i> , <b>2015</b> , 184, 863-70	1.9	3
83	Intestinal Adaptation45-54		3
82	Intestinal Transplantation: Indications and Patient Selection243-253		3
81	Small intestinal transplantation. <i>Current Gastroenterology Reports</i> , <b>2001</b> , 3, 408-11	5	3
80	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 1305-8	4	3
79	Lost microbes of COVID-19: , depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.. <i>BMJ Open Gastroenterology</i> , <b>2022</b> , 9,	3.9	3
78	What can we learn from other clinical settings on the influence of the gut microbiome on the brain?. <i>Clinical Liver Disease</i> , <b>2017</b> , 9, 52-54	2.2	2
77	The past 10 years of gastroenterology and hepatology-reflections and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 692-700	24.2	2
76	Commentary: Probing probiotics in cirrhosis--a template for future studies?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1334-5	6.1	2
75	Intestinal Morphology, Intestinal Regeneration and the Promise of Tissue Engineering11-19		2
74	Intestinal Failure-Associated Liver Disease191-200		2
73	Vascular Access, Including Complications142-150		2
72	The Enteric Flora in Intestinal Failure167-184		2
71	The Microbiome: What Will the Future Hold?. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 354-359	7.3	2
70	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , <b>2021</b> , 33, e14070	4	2

69	Definitions and Classifications of Irritable Bowel Syndrome1-21		2
68	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1254-1255	6.1	1
67	PARs for the course: roles of proteases and PAR receptors in subtly inflamed irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1644-6	0.7	1
66	Commentary: long-term lubiprostone for constipation predominant IBS. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 962-3	6.1	1
65	Infections in Small Bowel Transplant Recipients297-304		1
64	Enteral Support for Children with Intestinal Failure151-159		1
63	Management of Complex Fluid and Electrolyte Disturbances185-190		1
62	Isolated Small Bowel Transplantation and Combined Liver-Small Bowel Transplantation254-261		1
61	Preservation of the Intestine275-282		1
60	Immediate Postoperative Care of the Intestinal Transplant Recipient283-289		1
59	Financial, Economic and Insurance Issues Pertaining to Intestinal Transplantation: When is too much not enough?363-377		1
58	Inflammatory Bowel Disease and the Short Bowel Syndrome99-106		1
57	Guidelines for Home Parenteral Nutrition Support in Chronic Intestinal Failure Patients122-129		1
56	Intestinal motility: Normal and disturbed patterns. <i>Chinese Journal of Digestive Diseases</i> , <b>2003</b> , 4, 1-4		1
55	Probiotics and Irritable Bowel Syndrome. <i>Bioscience and Microflora</i> , <b>2009</b> , 28, 119-124		1
54	Autoimmune liver disease and the enteric microbiome. <i>AIMS Microbiology</i> , <b>2018</b> , 4, 334-346	4.5	1
53	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 8047-8061	5.6	1
52	The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , <b>2021</b> , 50, 689-711	4.4	1

51	The Use of Enteral Nutrition in the Adult with Intestinal Failure160-166		o
50	Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 6, 100171	1.9	o
49	Commentary: faecal microbiota transplantation-from home brew to holy grail. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 208-209	6.1	
48	Leadership in medicine: do we need a new approach?. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 786-8	0.7	
47	Gastrointestinal dysfunction in neurological disease: a report of an interdisciplinary international symposium. <i>Neurogastroenterology and Motility</i> , <b>2008</b> , 6, 55-57	4	
46	Assessment of Intestinal Failure Patients115-121		
45	Intestinal Failure: Definitions and Classifications55-65		
44	Immunology of the Small Intestine33-44		
43	Basic Physiology of Motility, Absorption and Secretion20-32		
42	The History of Intestinal Failure and Transplantation1-10		
41	Intestinal Failure Related to Bariatric Surgery93-98		
40	Motility Disorders107-113		
39	Psychiatric Issues in the Assessment of the Patient with Intestinal Failure201-205		
38	Munchausen Syndrome by Proxy206-211		
37	The Role of Humoral Factors in Intestinal Adaptation223-228		
36	Autologous Reconstruction of the GI Tract229-241		
35	Living Donor Intestinal Transplantation262-269		
34	Isolated Liver Transplantation for Intestinal Failure-Associated Liver Disease270-274		

33 Surgical Complications of Intestinal Transplantation 290-296

32 Immunosuppression after Intestinal Transplantation 305-313

31 Immunology of Intestinal Allograft Rejection 314-321

30 Histopathology of Intestinal Transplantation 322-330

29 Long-Term Management of Intestinal Transplant Recipients 331-341

28 Management of Posttransplant Lymphoproliferative Disease 342-348

27 Results of Intestinal Transplantation 349-356

26 Psychosocial Assessment and Management of the Transplant Patient/Family in Intestinal Transplantation 357-362

25 Causes of Intestinal Failure in the Newborn 66-76

24 Congenital Enteropathies Causing Permanent Intestinal Failure 77-87

23 Luminal Nutrient Factors in Intestinal Adaptation and their use in Therapy 213-222

22 Causes of Intestinal Failure in the Adult 88-92

21 Is there a future for a national scientific medical journal in Ireland?. *Irish Journal of Medical Science*, **2000**, 169, 12-12 1.9

20 Neuromuscular disorders in systemic malignancy and its treatment. *Muscle and Nerve*, **1996**, 19, 109-10 3.4

19 Development and evaluation in an ex vivo rat model of a technique for the endoscopic assessment of mucosal defense in man. *Scandinavian Journal of Gastroenterology*, **1991**, 26, 353-60 2.4

18 Antroduodenal manometry. *Digestive Diseases and Sciences*, **1992**, 37, 1927 4

17 Highlights of the Updated Evidence-Based IBS Treatment Monograph. *Gastroenterology and Hepatology*, **2018**, 14, 665-667 0.7

16 Food-related Symptoms of Irritable Bowel Syndrome 141-158

15 What is the Best Way to Identify and Quantify Irritable Bowel Syndrome?51-67

14 Interface between Primary Care and Secondary Care93-117

13 Epidemiology of Irritable Bowel Syndrome23-36

12 Gut Hypersensitivity Related Symptoms237-262

11 Abdominal Bloating263-276

10 Gut Inflammation in Irritable Bowel Syndrome159-181

9 Gut Motility Related Symptoms215-236

8 Diagnostic and Therapeutic Horizons for Irritable Bowel Syndrome301-314

7 Sequencing the Treatments277-299

6 Self-Management Strategies for Irritable Bowel Syndrome119-139

5 Psychological Factors and Treatments in Irritable Bowel Syndrome183-213

4 Practical Approach to Clinical Assessment of Irritable Bowel Syndrome69-91

3 Microbiome Modulation in Liver Disease. *Clinical Liver Disease*, **2019**, 14, 149-151

2.2

2 Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines. *Revista De Gastroenterologia Del Peru: Organo Oficial De La Sociedad De Gastroenterologia Del Peru*, **2020**, 40, 127-135

0.3

1 Bacterial overgrowth **2022**, 1155-1167